Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env

Vaccine

Volumn 18, Issue 27, 2000, Pages 3123-3133

  Collado, Manuel ^a   Rodríguez, Dolores ^a   Rodríguez, Juan Ramón ^a   Vázquez, Isabel ^a   Gonzalo, Rosa M ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Fusion proteins; HIV 1 env; Humoral and cellular responses; Vaccinia virus

Indexed keywords

CD8 ANTIGEN; CHIMERIC PROTEIN; EPITOPE; NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS; VIRUS INFECTION;

EID: 0342699577     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00112-2     Document Type: Article

References (40)

1. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its eradication. 1988;World Health Organisation, Geneva.
2. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proceedings of the National Academy of Sciences USA. 93:(21):1996;11341-11348.
3. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proceedings of the National Academy of Sciences USA. 93:(21):1996;11349-11353.
4. Chakrabarti S., Robert G.M., Wong S.F., Gallo R.C., Moss B. Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature. 320:(6062):1986;535-537.
5. Rodriguez D., Rodriguez J.R., Rodriguez J.F., Trauber D., Esteban M. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proceedings of the National Academy of Sciences USA. 86:(4):1989;1287-1291.
6. Cooney E.L., McElrath M.J., Corey L., Hu S.L., Collier A.C., Arditti D., Hoffman M., Coombs R.W., Smith G.E., Greenberg P.D. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proceedings of the National Academy of Sciences, USA. 90:(5):1993;1882-1886.
7. Graham B.S., Matthews T.J., Belshe R.B., Clements M.L., Dolin R., Wright P.F., Gorse G.J., Schwartz D.H., Keefer M.C., Bolognesi D.P., et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. Journal of Infectious Diseases. 167:(3):1993;533-537.
8. McElrath M.J., Corey L., Berger D., Hoffman M.C., Kluching S., Dragavon J., Peterson R., Greenberg P.D. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope proteins: analysis of the durability of responses and effect of repeated boosting. Journal of Infectious Diseases. 169:1994;41-47.
9. Egan M.A., Pavlat W.A., Tartaglia J., Paoletti E., Weinhold K.J., Clements M.L., Siliciano R.F. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. Journal of Infectious Diseases. 171:(6):1995;1623-1627.
10. Pialoux G., Excler J.L., Riviere Y., Gonzalez C.G., Feuillie V., Coulaud P., Gluckman J.C., Matthews T.J., Meignier B., Kieny M.P., et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI), The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Research and Human Retroviruses. 11:(3):1995;373-381. [published erratum appears in AIDS Res Hum Retroviruses 1995 Jul;11(7):875].
11. Fleury B., Janvier G., Pialoux G., Buseyne F., Robertson M.N., Tartaglia J., Paoletti E., Kieny M.P., Excler J.L., Riviere Y. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunised with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. Journal of Infectious Diseases. 174:(4):1996;734-738.
12. Katz E., Moss B. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. AIDS Research and Human Retroviruses. 13:(17):1997;1497-1500.
13. Tobery T.W., Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunisation. Journal of Experiemental Medicine. 185:(5):1997;909-920.
14. Rodriguez J.F., Janeczko R., Esteban M. Isolation and characterisation of neutralizing monoclonal antibodies to vaccinia virus. Journal of Virology. 56:(2):1985;482-488.
15. Vazquez M.-I., Rivas G., Cregut D., Serrano L., Esteban M. The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal a-helix. Journal of Virology. 72:1998;10126-10137.
16. Maa J.S., Esteban M. Structural and functional studies of a 39,000-Mr immunodominant protein of vaccinia virus. Journal of Virology. 61:(12):1987;3910-3919.
17. Demkowicz W.E., Maa J.S., Esteban M. Identification and characterisation of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. Journal of Virology. 66:(1):1992;386-398.
18. Rodriguez J.R., Rodriguez D., Esteban M. Structural properties of HIV-1 Env fused with the 14-kDa vaccinia virus envelope protein. Virology. 181:(2):1991;742-748.
19. Esteban M., Rodriguez J.R., Jimenez V., Rodriguez D. Use of persistent infections with vaccinia virus recombinants to introduce alterations in foreign proteins: an application to HIV-1 env protein. Virus Research. 46:(12):1996;45-56.
20. Rodriguez J.F., Rodriguez D., Rodriguez J.R., McGowan E.B., Esteban M. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proceedings of the National Academy of Sciences USA. 85:(5):1988;1667-1671.
21. Li S., Rodrigues M., Rodriguez D., Rodriguez J.R., Esteban M., Palese P., Nussenzweig R.S., Zavala F. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proceedings of the National Academy of Sciences USA. 90:(11):1993;5214-5218.
22. Takahashi H., Cohen J., Hosmalin A., Cease K.B., Houghten R., Cornette J.L., DeLisi C., Moss B., Germain R.N., Berzofsky J.A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognised by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences USA. 85:(9):1988;3105-3109.
23. Miyahira Y., Murata K., Rodriguez D., Rodriguez J.R., Esteban M., Rodrigues M.M., Zavala F. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. Journal of Immunological Methods. 181:(1):1995;45-54.
24. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clemens M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Walker M.C., Wagner K.F., Mcneil J.G., McCutchan F.E., Burke D.S. Immunisation with envelope subunit vaccine products elicit neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases Aids Vaccine Evaluation Group. Journal of Infectious Disease. 173:1996;340-348.
25. Palker T.J., Clark M.E., Langlois A.J., Matthews T.J., Weinhold K.J., Randall R.R., Bolognesi D.P., Haynes B.F. Type-specific neutralisation of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proceedings of the National Academy of Sciences USA. 85:(6):1988;1932-1936.
26. Haynes B.F., Pantaleo G., Fauci A.S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
27. Stamatos N.M., Mascola J.R., Kalyanaraman V.S., Londer M.K., Frampton L.M., Birx D.L., VanCott T.C. Neutralizing antibodies from sera of human immunodeficiency virus type 1 - infected individuals bind monomeric gp120 and oligomeric gp140. J. Virol. 72:1998;9656-9657.
28. Spenlehauer C., Saragosti S., Fleury H.J.A., Kirn A., Aubertin A.-M., Moog C. Study of the V3 loop as a target epitope for antibodies involved in the neutralisation of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. Journal of Virology. 72:1998;9855-9864.
29. Kwong P.D., Wyat R., Robinson J., Sweet R.W., Sodrosky J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and neutralizing human antibody. Nature. 393:1998;648-659.
30. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodrosky J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-711.
31. Carrow E.W., Vujcic L.K., Glass W.L., Seamon K.B., Rastogi S.C., Hendry R.M., Boulos R., Nzila N., Quinnan G.J. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Research and Human Retroviruses. 7:(10):1991;83-838.
32. Javaherian K., Langlois A.J., McDanal C., Ross K.L., Eckler L.I., Jellis C.L., Profy A.T., Rusche J.R., Bolognesi D.P., Putney S.D., Matthews T.J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proceedings of the National Academy of Sciences USA. 86:(17):1989;6768-6772.
33. Garrity R.R., Rimmelzwaan G., Minassian A., Tsai W.P., Lin GdeJ.J, Goudsmit J., Nara P.L. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. Journal of Immunology. 159:(1):1997;279-289.
34. Wyatt R., Moore J.P., Accola M., Desjardin E., Robinson J., Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. Journal of Virology. 69:1995;5723-5733.
35. Gorny M.K., Moore P.J., Couley A.J., Karwowska J., Sodrosky J., Williams C., Burda S., Boots L.J., Zora-Pazner S. Human anti-V2 monoclonal antibody that neutralises primary but not laboratory isolates of human immunodeficiency virus type 1. Journal of Virology. 68:1994;8312-8320.
36. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas C.F. III, Burton D.R., Ho D.D., Moore J.P. Cross-clade neutralisation of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-immunoglobulin G. Journal of Virology. 69:1995;6609-6617.
37. LaCasse R.A., Follis K.E., Trahey M., Scarborough J.D., Littman D.R., Nunberg J.H. Fusion-competent vaccines: broad neutralisation of primary isolates of HIV. Science. 283:(5400):1999;357-362.
38. Miyahira Y., Garcia-Sastre A., Rodriguez D., Rodriguez J.R., Tsuji M., Palese P., Esteban M., Zavala F., Nussenzweig R.S. Recombinant viruses expressing a human malaria antigen elicit a protective immune response in mice. Proceedings of the National Academy of Sciences USA. 95:1998;3954-3959.
39. Hanke T., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., Hill A.V., Smith G.L., McMichael A. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 16:1998;439-446.
40. Gonzalo R.M., Rodriguez D., Garcia-Sastre A., Rodriguez J.R., Palese P., Esteban M. Enhnced CD8+ T cell response to HIV-1 env by combined immunisation with influenza and vaccinia virus recombinants. Vaccine. 17:1999;887-892.